Relapse or Refractory Myeloid Malignancies: Clinical Trials

1 trial for Relapse or Refractory Myeloid Malignancies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 recruiting. 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 11Recruiting 1

Follow Relapse or Refractory Myeloid Malignancies: new trials by email Literature Review of Relapse or Refractory Myeloid Malignancies trials Research Report on Relapse or Refractory Myeloid Malignancies

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.
CBX-663 - Advanced Solid Tumors, Recurrent or Progressive Glioblastoma
Phase 1RecruitingCrossbow Therapeutics, Inc.1202026-08-042026-10-21

Narrower conditions

Recurrence (1)

Broader conditions

Disease Attributes (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Sponsors

Crossbow Therapeutics, Inc. (1)

Countries

United States (1)